Patients diagnosed with ALS receive a multidisciplinary evaluation every 3 months. In addition, we provide medical, social and home support. To share our expertise regarding care for ALS patients, we provide training sessions for medical and paramedical staff, and organise a symposium with other French ALS Centers. Our research interests include epidemiology, cognition and nutrition. To this extent, we establish internal and multicenter research protocols and collaborate with the pharmaceutical industry in therapeutic research.
Contact
Location2 Avenue Martin Luther King, Limoges, France
Our Specialists
Current trials
Recruiting
Phase iii
ATLAS trial
Industry trial
Biogen is conducting a clinical trial to evaluate the efficacy and safety and of an investigational drug for adults who do not have any clinical signs or symptoms of Amyotrophic Lateral Sclerosis (ALS) (that definitely indicate the onset of ALS) but do carry a certain superoxide dismutase 1 (SOD1) gene variant.
Recruiting
Phase iii
FUSION trial
Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Active
Phase iii
PHOENIX trial
Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Active
Phase iii
ADORE trial
Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Recruiting
Phase iii
COURAGE-ALS Trial
Industry trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Active
Phase ii
APL2-ALS-206 Trial
Industry trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
Active
Phase iii
TUDCA-ALS
Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.